Mocetinostat, an HDACi, efficiently reduced the expression of ZEB1 in pancreatic tumour cells (87), revealing a therapeutic effect of class I HDACis in treating EMT and metastasis of cancers. Here, ZEB1 is linked to pancreatic neoplasm.